Caribou Biosciences Files Routine 8-K on Jan 7 Event

TL;DR

**Caribou Biosciences filed a routine 8-K, no major news.**

AI Summary

Caribou Biosciences, Inc. filed an 8-K on January 8, 2024, reporting an event that occurred on January 7, 2024. This filing is a routine disclosure under Regulation FD and Other Events, indicating no major financial or operational changes. For investors, this means there's no immediate new information that would significantly alter the company's valuation or outlook, suggesting a period of stability or lack of new material developments.

Why It Matters

This filing is a standard disclosure, indicating no significant new developments that would immediately impact Caribou Biosciences' stock price or business operations.

Risk Assessment

Risk Level: low — The filing is a standard disclosure with no specific financial or operational details that would introduce new risks.

Analyst Insight

A smart investor would note this as a routine filing without new material information, suggesting no immediate action is required based solely on this 8-K. Further research into other company news or financial statements would be necessary for investment decisions.

Key Players & Entities

• Caribou Biosciences, Inc. (company) — the registrant filing the 8-K
• January 7, 2024 (date) — date of the earliest event reported
• January 8, 2024 (date) — date the 8-K was filed
• 001-40631 (other) — Commission File Number
• CRBU (other) — Trading Symbol for Common Stock
• NASDAQ Global Select Market (other) — exchange where Common Stock is registered

FAQ

Key Financial Figures

• $0.0001 — ange on which registered Common Stock, $0.0001 par value per share CRBU NASDAQ Global

Filing Documents

• crbu-20240107.htm (8-K) — 33KB
• crbu-20240108xexx991.htm (EX-99.1) — 38KB
• img25401123_0a.jpg (GRAPHIC) — 51KB
• 0001619856-24-000003.txt ( ) — 284KB
• crbu-20240107.xsd (EX-101.SCH) — 2KB
• crbu-20240107_lab.xml (EX-101.LAB) — 25KB
• crbu-20240107_pre.xml (EX-101.PRE) — 13KB
• crbu-20240107_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 7, 2024, Caribou Biosciences, Inc. ("Caribou" or the "Company") issued a press release announcing the appointment of Tim Kelly as Chief Technology Officer of the Company, highlighting 2023 clinical events and corporate accomplishments, and providing an outlook of anticipated 2024 clinical milestones. A copy of the press release is furnished herewith as Exhibit 99.1 and also is incorporated by reference into this Item 7.01. The information set forth under this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing under the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing.

01 Other Events

Item 8.01 Other Events. On January 7, 2024, the Company issued a press release announcing the appointment of Tim Kelly as Chief Technology Officer of the Company.

Forward-Looking Statements

Forward-Looking Statements This Current Report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not historical facts are forward-looking statements. Forward-looking statements may relate to future events or future performance. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about the Company, its industry, its beliefs, and its assumptions. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential," or "continue" or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, without limitation, statements related to Caribou's strategy, plans, and objectives, and expectations regarding its clinical and preclinical development programs, including its expectations relating to the timing of status and updates from its ANTLER phase 1 clinical trial for CB-010, including expectations regarding the timing of reporting initial dose expansion data from the ANTLER trial and disclosure of the recommended phase 2 dose for CB-010, its planned phase 3 pivotal trial for CB-010 in second-line relapsed or refractory large B cell lymphoma patients, the status and updates from its CaMMouflage phase 1 clinical trial for CB-011 and expectations regarding the timing of reporting initial dose escalation data, expectations regarding the timing of initiating patient enrollment in the AMpLify phase 1 clinical trial for CB-012, and Caribou's expected cash runway. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements are subject to risks and uncertainties, and actual results may

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release Issued by Caribou Biosciences, Inc. on Januar y 7 , 202 4 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Caribou Biosciences, Inc. Date: January 8, 2024 By: /s/ Rachel E. Haurwitz Rachel E. Haurwitz President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR